
Opthea (OPT) Stock Forecast & Price Target
Opthea (OPT) Analyst Ratings
Bulls say
Opthea Ltd is advancing its development of OPT-302, a novel biologic therapy aimed at addressing eye diseases associated with vascular growth and leakage, supported by its intellectual property portfolio focusing on key targets such as VEGF-C and VEGF-D. The company is approaching pivotal Phase 3 COAST trial topline results projected for early Q2 CY2025, with strong interim data indicating significant visual acuity improvements, particularly a +5.7 letter gain among high responder subgroups, which enhances the feasibility of broad adoption among retinal specialists. Additionally, feedback from surveyed payers suggests that achieving a minimum of 20% improvement in vision could lead to favorable coverage decisions, reflecting the strong clinical relevance of Opthea's therapeutic developments in the competitive landscape of ophthalmology treatments.
Bears say
Opthea Ltd reported a significant net loss of $131.9 million, translating to $0.11 per share for the first half of fiscal year 2025, indicating financial challenges. The company faces several substantial risks, including the potential failure of its developmental candidate, OPT-302, to achieve projected peak commercial revenues due to factors such as market size and pricing pressures. Additionally, difficulties in securing necessary capital to fund operations and ongoing program development pose further threats to the company's financial health and viability.
This aggregate rating is based on analysts' research of Opthea and is not a guaranteed prediction by Public.com or investment advice.
Opthea (OPT) Analyst Forecast & Price Prediction
Start investing in Opthea (OPT)
Order type
Buy in
Order amount
Est. shares
0 shares